In Focus: studying the COVID-19 pandemic – a Special Focus Issue
Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
Browsing: Vaccines
AstraZeneca COVID-19 vaccine trial resumed in the UK after safety evaluation
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.
Cytokine storm could sabotage long-term immunity against SARS-CoV-2
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
Countries with previous TB vaccine coverage show improved COVID-19 outcomes
An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
Oxford vaccine gives strong immune response against COVID-19
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
Novel adjuvant helps extend immunity against HIV in primates
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
A closer look at the COVID-19 vaccine front-runners
A COVID-19 vaccine is widely regarded as the panacea for a fast track to normal life. There are currently over 120 vaccine candidates in development, with ten already in clinical trials. Take a look at the front-runners.
Researchers repurpose cancer immunotherapy tools for COVID-19 vaccine research
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
Using a novel approach for malaria vaccine development – an interview with Jonathan Kurtis
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
First human COVID-19 vaccine trial displays promising results
The first human trial testing a potential COVID-19 vaccine has been successful, with initial results suggesting the vaccine is safe and capable of generating an immune response against SARS-CoV-2 in humans.
